Our objective was to assess, using clinical trial simulation, the feasibility of a fixed 200-µg dose of darbepoetin alfa (Aranesp) administered every 2 weeks in chemotherapy-induced anemia. A pharmacokinetic/pharmacodynamic
Gregory Rossi, PhD
Advertisement
Articles by Gregory Rossi, PhD
Our objective was to evaluate the effects of darbepoetin alfa (Aranesp) on hemoglobin and transfusions in anemic patients with cancer undergoing chemotherapy, and the impact of age, sex, baseline hemoglobin, chemotherapy
The safety and efficacy of darbepoetin alfa (Aranesp) at 3.0 µg/kg administered every 2 weeks and recombinant human erythropoietin (rHuEPO) given as 40,000 U weekly or 150 U/kg three times weekly were evaluated by
Advertisement
Latest Updated Articles
- Clinical Trial Simulation of a 200-µg Fixed Dose of Darbepoetin Alfa in Chemotherapy-Induced Anemia
Published: October 1st 2002 | Updated:
- Darbepoetin Alfa: Impact on Treatment for Chemotherapy-Induced Anemia and Considerations in Special Populations
Published: October 1st 2002 | Updated:
- Every-2-Week Darbepoetin Alfa Is Comparable to rHuEPO in Treating Chemotherapy-Induced Anemia
Published: October 1st 2002 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights
2
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
3
BL-B01D1 Shows Preliminary Efficacy, Favorable Safety in Urothelial Cancer
4
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
5
